10-Q: Cryo-Cell International Faces Significant Headwinds as Duke License Agreement Terminated Amidst Arbitration Battle

Cryo-Cell International, Inc. reported a significant decline in net income for the six months ended May 31, 2025, primarily impacted by increased expenses and the termination of its crucial license agreement with Duke University, which has halted key strategic growth initiatives.

Summary

• Total revenue for the six months ended May 31, 2025, was $15,897,723, a slight increase from $15,895,046 for the same period in 2024.
• Net income for the six months ended May 31, 2025, decreased significantly to $638,640, down from $1,212,031 in the comparable 2024 period.
• Processing and storage fees, the primary revenue source, decreased to $15,737,607 for the six months ended May 31, 2025, from $15,771,022 in 2024, driven by a 15% decrease in new domestic cord blood specimens, partially offset by a 4% increase in recurring annual storage fee revenue.
• Selling, general and administrative expenses increased by 7% to $8,896,142 for the six months ended May 31, 2025, compared to $8,352,129 in 2024.
• Research, development and related engineering expenses significantly decreased to $229,854 for the six months ended May 31, 2025, from $743,974 in 2024, largely due to the cessation of funding for the Duke IMPACT Study and Emmes clinical trials.
• Interest expense rose substantially to $1,046,088 for the six months ended May 31, 2025, from $585,732 in 2024.
• Cash and cash equivalents decreased to $137,491 as of May 31, 2025, from $560,960 as of November 30, 2024.
• The company's revolving line of credit balance increased to $6,620,000 as of May 31, 2025, from $3,520,000 as of November 30, 2024.
• The Duke License Agreement was terminated by Duke University as of May 17, 2025, following Cryo-Cell's arbitration demand against Duke seeking over $100 million in damages.
• The proposed spinoff of Celle Corp. and the opening of the Cryo-Cell Institute for Cellular Therapies are on hold due to the Duke dispute.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to a significant decline in net income, a substantial increase in debt utilization, and the critical setback of the Duke License Agreement termination. This legal dispute and the resulting halt of major growth initiatives create considerable uncertainty and undermine the company's strategic direction, outweighing minor positives like cost of sales reduction or recurring revenue growth.

Positives

• Total revenue for the six months ended May 31, 2025, saw a slight increase to $15,897,723 compared to $15,895,046 in the prior year.
• Recurring annual storage fee revenue increased by 4% for the six months ended May 31, 2025.
• Public cord blood banking revenue increased to $124,767 for the six months ended May 31, 2025, from $85,190 in the prior year, indicating growth in this segment.
• Cost of sales decreased by 8% for the six months ended May 31, 2025, to $3,841,127, compared to $4,185,218 in 2024.
• Research, development and related engineering expenses significantly decreased, reflecting reduced spending on the Duke IMPACT Study and Emmes clinical trials.
• The company terminated its interest rate swap agreement on April 15, 2024, recording proceeds of $228,000.
• The company continues to repurchase its common stock, acquiring 18,008 shares during the six months ended May 31, 2025, at an average price of $4.92 per share, demonstrating commitment to shareholder returns.
• The company introduced ExtraVault, a new cold storage service for third-party pharmaceutical companies and medical institutions, leveraging its new Durham, NC facility.

Negatives

• Net income for the six months ended May 31, 2025, decreased by 47.3% to $638,640 from $1,212,031 in the comparable 2024 period.
• Net income per common share (basic and diluted) decreased to $0.08 for the six months ended May 31, 2025, from $0.15 in 2024.
• Processing and storage fees, the core revenue stream, decreased due to a 15% decline in new domestic cord blood specimens processed.
• Selling, general and administrative expenses increased by 7% for the six months ended May 31, 2025, impacting profitability.
• Interest expense increased significantly by 78.6% to $1,046,088 for the six months ended May 31, 2025, from $585,732 in 2024.
• Cash and cash equivalents decreased by 75.5% from $560,960 at November 30, 2024, to $137,491 at May 31, 2025.
• The company's line of credit utilization increased substantially to $6,620,000 at May 31, 2025, from $3,520,000 at November 30, 2024.
• The Duke License Agreement, central to the company's planned expansion into infusion clinic services and biopharmaceutical manufacturing, has been terminated by Duke University.
• The proposed spinoff of Celle Corp. and the opening of the Cryo-Cell Institute for Cellular Therapies are on hold indefinitely due to the ongoing dispute with Duke.
• The company recorded an impairment charge of $13,108,064 in fiscal 2023 related to the Duke License Agreement assets, indicating a significant loss on this strategic investment.

Risks

• Uncertainty regarding the ability to maximize shareholder value through a strategic transaction or the successful spinoff of Celle Corp. due to the Duke arbitration.
• Potential delisting from NYSE American LLC if the company fails to comply with continued listing standards.
• Need to raise additional capital, especially if the Duke dispute requires continued investment or if expected revenue increases are not realized.
• Inability to successfully grow or effectively operate the business, including achieving widespread market acceptance of cryopreservation of stem cells.
• Adverse macroeconomic conditions, including inflation, slower growth, recession, tariffs, and higher interest rates, could negatively impact demand and liquidity.
• Rapid technological and therapeutic changes could render current stem cell uses or equipment obsolete.
• Failure to successfully or profitably manufacture Mesenchymal Stromal Cells (MSCs) or negative results in clinical trials for efficacy.
• Uncertainty and potential delays in clinical trials and regulatory approval processes for product candidates.
• Increasing competition in the stem cell preservation market from other operators and public cord blood banks.
• Risk of failure or malfunction in cryopreservation storage facilities or systems, including those used by Duke for public cord blood specimens, potentially leading to specimen damage, litigation, and reputational harm.
• Inability to retain key personnel or attract and retain additional qualified staff (software developers, bioinformaticists, operations, sales, marketing, business development).
• Uncertain outcome of the Duke Arbitration Demand, with potential for unfavorable resolution, significant costs, and inability to recoup damages or investment.
• General exposure to legal proceedings, lawsuits, and contract disputes in the normal course of business.
• Failure to obtain and maintain necessary domestic regulatory registrations, approvals, and compliance with ongoing regulations (e.g., FDA, state licenses).
• Substantial costs and management effort required to comply with patient privacy laws (HIPAA, HITECH Act), with potential for criminal and civil penalties for non-compliance.
• Failure to comply with laws related to hazardous materials, leading to liability or increased costs.
• Risks associated with international operations, including intellectual property protection, local business laws, political/economic instability, currency fluctuations, contract enforcement, and compliance with anti-corruption laws.
• Vulnerability of information systems to damage, interruption, unauthorized access, cyber-attacks, ransomware, and viruses, potentially leading to data breaches, litigation, and reputational damage.
• Increasing use of social media by the company and employees could lead to liability, data security breaches, or reputational damage.
• Risks associated with the use of open source software, including unanticipated license conditions, claims of ownership, and lack of support.
• Significant costs and demands of operating as a public company, including compliance with Sarbanes-Oxley, Dodd-Frank, and NYSE requirements.
• Risk of not maintaining an effective system of internal control over financial reporting, which could adversely affect investor confidence.
• Limitations on the effectiveness of controls, as no system can prevent all error or fraud.
• Increasing scrutiny and changing expectations from investors, customers, and governments regarding Environmental, Social and Governance (ESG) policies and practices.
• Concentration of control by principal stockholders and management, potentially delaying or preventing acquisitions.
• Potential for securities class action litigation, which can be expensive and divert management attention.
• Status as a smaller reporting company may make common stock less attractive to investors due to reduced disclosure requirements.
• Indemnification of officers and directors could result in substantial expenditures.
• Certain provisions of the company's charter, bylaws, and Delaware law may delay, defer, or prevent a tender offer or takeover attempt.

Future Outlook

The company's future outlook is highly uncertain due to the termination of the Duke License Agreement and the ongoing arbitration. It is unlikely to expand its business into infusion clinic services and biopharmaceutical manufacturing through the Duke License Agreement. The opening of the Cryo-Cell Institute for Cellular Therapies is on pause, and the proposed spinoff of Celle Corp. is on hold. The company does not anticipate making further significant investments in Duke-related activities (beyond a comparability study estimated at less than $350,000) until the dispute is resolved. Future funding needs for these initiatives are currently unpredictable. The company anticipates its current cash, marketable securities, and cash flows from operations, along with external capital, will be sufficient for the next 12 months, but this depends on increasing revenues and managing discretionary expenses. There are no assurances that additional debt or equity financing will be obtainable on favorable terms or at all, and reductions in expenditures may be necessary, potentially adversely affecting business operations and new service development.

Management Comments

• Management believes that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments.
• Management believes that the fair value of its Revenue Sharing Agreements (RSAs) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA.
• Management believes that the investment in Tianhe stock is fully impaired due to the lack of activity and profits.
• Management believes the plaintiff's claims in the Lindsey Lehr v. Cryo-Cell International, Inc. case are unlikely to prevail and is contesting the action vigorously.
• Management believes that the resolution of the Lindsey Lehr matter should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations.
• Management believes Duke’s counterclaims are without merit and intends to contest them vigorously.
• Management believes that the resolution of the Duke counterclaims should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations.
• Management does not expect that disclosure controls and internal controls will prevent all error and all fraud, acknowledging inherent limitations.
• Management anticipates making discretionary capital expenditures of approximately $5,000,000 over the next twelve months for property build out, purchases of equipment and software enhancements.
• Management anticipates funding future property build out, equipment purchases and software enhancements with cash-on-hand, cash flows from future operations, the Company’s revolving line of credit and potential additional debt financing.
• Management previously anticipated that over $50 million would be needed over the next 5 years to fund its activities related to the Duke License Agreement, but is now unable to predict funding needs due to the arbitration.
• Management anticipates that its cash and cash equivalents, marketable securities and cash flows from operation, together with external sources of capital will be sufficient to fund its known cash needs for at least the next 12 months.

Industry Context

Cryo-Cell International operates in the highly specialized and evolving field of cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells. The industry is characterized by rapid technological and therapeutic advancements, increasing competition from both private and public cord blood banks, and stringent government regulations. The company's efforts to expand into infusion clinic services and biopharmaceutical manufacturing through the Duke License Agreement reflect a broader industry trend towards leveraging stored biological materials for advanced therapeutic applications. However, the termination of this key agreement and the ongoing legal dispute with Duke University represent a significant setback, potentially limiting Cryo-Cell's ability to capitalize on these emerging opportunities and compete effectively in the broader regenerative medicine landscape. The introduction of ExtraVault, a third-party cold storage service, indicates a strategic pivot to diversify revenue streams within its core competency of cryopreservation, potentially addressing the growing demand for biorepository services from biopharmaceutical companies.

Comparison to Industry Standards

• The company's core business of umbilical cord blood and tissue stem cell storage is a well-established segment within the broader regenerative medicine industry. Its long history (first private cord blood bank in 1992) and accreditations (cGMP/cGTP-compliant, AABB, FACT) suggest adherence to high industry standards for quality and operational excellence.
• The reported 100% viability rate of specimens upon thaw for therapeutic use since inception is a strong indicator of quality and reliability, potentially exceeding the average for some less established or less rigorously controlled banks.
• The company's payment warranty (up to $100,000 for PrepaCyte CB clients) for engraftment failure is a competitive differentiator, offering a level of assurance that may not be universally matched by all competitors in the private cord blood banking space.
• The decline in new domestic cord blood specimens processed (15% decrease) suggests a potential struggle in new client acquisition compared to the overall market, which may be influenced by increased competition from other private banks like ViaCord, Cord Blood Registry (CBR), or public banking initiatives, or a general slowdown in market penetration.
• The significant legal dispute with Duke University and the termination of the license agreement represent a major deviation from industry best practices for strategic partnerships, as such disputes can severely impede innovation and market expansion, unlike companies with stable, long-term research collaborations (e.g., larger pharmaceutical companies with academic institutions).
• The pivot to ExtraVault, offering third-party cold storage, aligns with a growing need for specialized biorepository services in the biopharma sector, a trend seen with companies like BioLife Solutions or Brooks Automation (now Azenta Life Sciences) which provide cold chain and sample management solutions. This diversification could be a positive move if executed effectively, especially given the challenges with the Duke agreement.

Legal Proceedings

• Lindsey Lehr v. Cryo-Cell International, Inc. (Case No. 50-2023-CA-000091): A class action complaint filed on January 6, 2023, alleging inaccurate advertising of services. The case was removed to federal court, and arbitration was compelled on October 10, 2023. The plaintiff dropped class action allegations on January 18, 2024, and a final hearing on individual claims and the company's counterclaim is scheduled for September 2025. The company believes the claims are unlikely to prevail.
• Arbitration Demand against Duke University: Filed on October 4, 2024, alleging fraudulent inducement and breach of the Patent and Technology License Agreement, seeking damages in excess of $100 million. Duke responded with counterclaims on November 18, 2024 (amended March 24, 2025) for breach and indemnity. Duke issued a notice of termination of the License Agreement as of May 17, 2025. The company believes Duke's counterclaims are without merit.

Stakeholder Impact

• **Shareholders**: Negative impact due to significant decline in net income, increased debt, and the termination of the Duke License Agreement, which puts major growth initiatives and the Celle Corp. spinoff on hold. The ongoing legal disputes introduce substantial uncertainty and risk to future profitability and share value. Dividends were paid, but future sustainability is questionable given financial performance.
• **Customers**: Potential impact on customers who enrolled with expectations of future therapies or services tied to the Duke License Agreement, as these are now unlikely to materialize through this agreement. The core processing and storage services continue, but a decrease in new domestic cord blood specimens suggests challenges in attracting new clients.
• **Employees**: Uncertainty regarding the future direction of the company, particularly for those involved in R&D or planned expansion initiatives related to the Duke agreement. The halt of the Cryo-Cell Institute for Cellular Therapies could affect job security or growth opportunities in those areas.
• **Creditors (Susser Bank)**: The company's increased utilization of its revolving line of credit and the extension of its maturity date indicate reliance on this financing. The ongoing legal dispute with Duke could impact the company's financial stability and ability to meet future obligations, although the company states it expects to have sufficient funds for the next 12 months.
• **Duke University**: Engaged in a significant legal dispute with Cryo-Cell, involving allegations of fraudulent inducement and breach of contract, and counterclaims. This will involve substantial legal costs and reputational risk for both parties.

Next Steps

• Continue vigorously contesting the Lindsey Lehr class action lawsuit, with a final hearing scheduled for September 2025.
• Vigorously contest Duke University's counterclaims in the ongoing arbitration.
• Complete a comparability study estimated to cost less than $350,000 related to Duke License Agreement activities, but no further significant investments are anticipated until the Duke dispute is resolved.
• Monitor and manage cash resources to meet needs for the next 12 months, potentially reducing or deferring cash expenditures if revenues are not realized or expenses are higher than anticipated.
• Evaluate the impact of new accounting pronouncements (ASU 2023-07, ASU 2023-09, ASU 2024-03) on financial statements and disclosures.
• Continue to market cord blood and cord tissue banking services, relying on online advertising and field educators to enroll new clients.
• Leverage the new Durham, NC facility to expand the ExtraVault cold storage business for third-party pharmaceutical companies and medical institutions.

Key Dates

Recommendation

Keywords

Cryo-Cell, Stem Cell Banking, Cord Blood Storage, Cryopreservation, Biotechnology, Cellular Therapy, PrepaCyte CB, ExtraVault, SEC Filing, 10-Q, Financial Results, Legal Dispute, Duke University, Arbitration, Celle Corp, Biopharmaceutical Manufacturing, Clinical Trials, Healthcare, Medical Technology, Regenerative Medicine